2025年 中国干细胞行业发展现状及趋 势洞察行业研究报告 2025 China Stem Cell Development Status and Trend Insights Industry Overview 概览标签：干细胞、细胞医疗服务、细胞治疗、细胞存储 报告主要作者：孙榕、姚雪闻 2025/12 1 www.leadleo.com ©2025 LeadLeo 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均 系头豹研究院独有的高度机密性文件（在报告中另行标明出处者除外 ）。 ，任何人不得以任何方式擅自复制 、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述 约定的行为发生，头豹研究院保留采取法律措施，追究相关人员责任 的权利。头豹研究院开展的所有商业活动均使用"头豹研究院"或"头豹 "的商号、商标，头豹研究院无任何前述名称之外的其他分支机构， 也未授权或聘用其他任何第三方代表头豹研究院开展商业活动。 www.leadleo.com 研究目的&摘要 研究目的 本报告为2025年中国干细胞行业发展现状 及趋势洞察研究报告，将通过分析产业链 上下游各环节以及各细分行业市场现状， 从 ...

2025年1至6月份，*ST生物的营业收入构成为：干细胞行业占比83.88%，节能技术服务行业占比 15.87%，其他业务占比0.25%。 （记者 曾健辉） 截至发稿，*ST生物市值为31亿元。 每经AI快讯，*ST生物（SZ 000504，收盘价：9.35元）11月28日晚间发布公告称，公司第十二届第六次 董事会会议于2025年11月28日以通讯方式召开。会议审议了《关于聘请2025年度审计机构的议案》等文 件。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 ...

Group 1 - The core point of the article is that *ST Bio announced a board meeting to discuss a proposal regarding debt transfer and related transactions [1] - For the first half of 2025, *ST Bio's revenue composition is as follows: stem cell industry accounts for 83.88%, energy-saving technology services account for 15.87%, and other businesses account for 0.25% [1] - As of the report date, *ST Bio has a market capitalization of 3.4 billion yuan [1]

Market Overview - The A-share market saw a majority of indices decline today, with the Shanghai Composite Index down 0.07% closing at 4000.14 points, the Shenzhen Component down 0.36% at 13240.62 points, the Sci-Tech 50 down 0.58% at 1379.45 points, and the ChiNext Index down 0.39% at 3122.03 points [1][10] - Overall, there were 1756 stocks that rose and 3561 that fell, with a total market turnover of 19450 billion yuan, a decrease of 485 billion yuan compared to the previous trading day [1] Industry Performance - Among the Shenwan first-level industries, the top gainers included household appliances (up 1.22%), comprehensive (up 1.05%), textile and apparel (up 0.87%), petroleum and petrochemicals (up 0.84%), and pharmaceutical and biological (up 0.61%) [1] - The leading decliners were in the sectors of electric equipment (down 2.10%), machinery equipment (down 1.23%), computers (down 1.04%), national defense and military industry (down 0.87%), and automobiles (down 0.81%) [1] Concept Sector Performance - The concept sectors with the highest gains included insurance selection, lithium battery electrolyte, blood products, stem cells, SPD, in vitro diagnostics, genetic testing, white household appliances selection, aluminum industry, three-child policy, industrial metals selection, synthetic biology, satellite internet, weight loss drugs, and central enterprise banks [2]

Group 1 - The company *ST Bio (SZ 000504) announced that its 12th fourth board meeting was held on October 24, 2025, via communication method, where the proposal for the "2025 Q3 Report" was reviewed [1] - For the first half of 2025, the revenue composition of *ST Bio was as follows: stem cell industry accounted for 83.88%, energy-saving technology services accounted for 15.87%, and other businesses accounted for 0.25% [1] - As of the time of reporting, *ST Bio's market capitalization was 3.1 billion yuan [1]

Group 1 - The core point of the article is that *ST Bio (SZ 000504) held its 12th third board meeting on September 5, 2025, to discuss the proposal for the third temporary shareholders' meeting of 2025 [1] - For the first half of 2025, *ST Bio's revenue composition was as follows: stem cell industry accounted for 83.88%, energy-saving technology services accounted for 15.87%, and other businesses accounted for 0.25% [1] - As of the time of reporting, *ST Bio's market capitalization was 3.2 billion yuan [1] Group 2 - The article also mentions that Haidilao is diversifying into various businesses, including opening a bakery by West Lake and entering the high-end hotel sector, but the survival rate of its sub-brands is less than 50% [1]

Group 1 - The company *ST Bio (SZ 000504) announced that its major shareholder, Chongqing International Trust Co., Ltd., has had 35.6 million shares judicially frozen, representing 100% of its holdings and 10.79% of the company's total share capital [1][1][1] - As of the announcement date, the company's market capitalization is 3.1 billion yuan [2] - For the first half of 2025, the company's revenue composition is as follows: stem cell industry accounts for 83.88%, energy-saving technology services account for 15.87%, and other businesses account for 0.25% [1][1][1]

Group 1 - The core point of the article is that *ST Bio is planning to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will make Huize a subsidiary and included in the consolidated financial statements after the transaction is completed [2] Group 2 - For the fiscal year 2024, *ST Bio's revenue composition is as follows: 73.32% from the stem cell industry, 26.54% from energy-saving technology services, and 0.14% from other industries [2]

Group 1 - The company *ST Bio (SZ 000504) announced that its 12th first board meeting was held via communication on August 8, 2025, where it reviewed the proposal to amend the "Audit Committee Work Rules" [2] - For the year 2024, the revenue composition of *ST Bio is as follows: stem cell industry accounts for 73.32%, energy-saving technology services account for 26.54%, and other industries account for 0.14% [2]

Group 1 - Han Kong Holdings (01663.HK) closed at HKD 0.077 on July 30, down 1.28% from the previous trading day, with an intraday low of HKD 0.074, marking a new low for the past year [1] - The net capital outflow for the day was HKD 1.45 million, with no significant inflow or outflow reported [1] - Han Kong Holdings, formerly known as Han Kong Real Estate Group, is a seasoned real estate developer focused on second and third-tier cities in China, headquartered in Hong Kong [1] Group 2 - The company is actively seeking new opportunities to diversify its revenue and enhance profitability, leading to its name change to Han Kong Holdings [1] - Han Kong Holdings is working on establishing a leading domestic contract research organization (CRO) platform in the pharmaceutical research sector and has entered the stem cell industry [1]